[go: up one dir, main page]

AR082458A1 - Combinacion que comprende un farmaco antipsicotico y un agonista de taar1 - Google Patents

Combinacion que comprende un farmaco antipsicotico y un agonista de taar1

Info

Publication number
AR082458A1
AR082458A1 ARP110102780A AR082458A1 AR 082458 A1 AR082458 A1 AR 082458A1 AR P110102780 A ARP110102780 A AR P110102780A AR 082458 A1 AR082458 A1 AR 082458A1
Authority
AR
Argentina
Prior art keywords
phenyl
lower alkyl
halogen
hydrogen
dihydro
Prior art date
Application number
Other languages
English (en)
Inventor
Marius Hoener
Susanne Raab
Celine Risterucci
Sabine Sewing
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44512842&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR082458(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR082458A1 publication Critical patent/AR082458A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Combinación farmacéutica destinada al tratamiento de la esquizofrenia y de episodios maniacos agudos asociados a trastornos bipolares, que comprende un compuesto que es activo sobre un receptor 1 asociado a aminas traza (agonista TAAR1) y un fármaco antipsicótico. Composiciones farmacéuticas que comprenden una combinación de un fármaco antipsicótico atípico y un agonista de TAAR1 tal como se describe en reivindicación 2, 3 y 4.Reivindicación 1: Combinación que comprende un fármaco antipsicótico atípico y un agonista de TAAR1. Reivindicación 2: Combinación según la reivindicación 1, que comprende olanzapina y un agonista de TAAR1 de fórmula (1) en la que: R1 es hidrógeno, deuterio, tritio, alquilo inferior, hidroxi, alcoxi inferior, alquilo inferior sustituido con halógeno, alcoxi inferior sustituido con halógeno, halógeno, fenilo opcionalmente sustituido con halógeno, o es feniloxi, bencilo, benciloxi, -COO-alquilo inferior, -O-(CH2)o-O-alquilo inferior, NH-cicloalquilo, cicloalquilo o tetrahidropirán-4-iloxi, en los que los sustituyentes para n > 1 pueden ser iguales o diferentes; X es un enlace, -CHR-, -CHRCHR’-, -OCH2-, -NRCHR’, -OCHRCHR’, -CH2OCHR-, -CH2CH2CH2-, -SCH2-, -S(O)2CH2-, -CH2SCH2-, -CH2N(R)CH2-, -cicloalquil-CH2- o SiRR’-CH2-; R/R’ puede ser, independientemente uno de otro, hidrógeno, alquilo inferior o alquilo inferior sustituido con halógeno; R2 es hidrógeno, fenilo o alquilo inferior; Y es fenilo, naftilo, tiofenilo, piridinilo, cicloalquilo, 1,2,3,4-tetrahidronaftalén-2-ilo, 2,3-dihidrobenzo[1,4]dioxin-6-ilo o benzo[1,3jdioxol-5-ilo; n es 0, 1, 2 ó 3; o es 2 ó 3; o una sal de adición de ácido farmacéuticamente aceptable de los mismos, o un agonista de TAAR1 de fórmula (2) en la que R es hidrógeno o alquilo inferior; R1 es -(CH2)n-(O)o-heterocicloalquilo, opcionalmente sustituido con alquilo inferior, hidroxi, halógeno, o con -(CH2)p-arilo; n es 0, 1 ó 2; o es 0 ó1; p es 0, 1 ó 2; R2 es cicloalquilo, heterocicloalquilo, o es arilo o heteroarilo, en el que los anillos aromáticos se sustituyen opcionalmente con uno o dos sustituyentes, seleccionados de entre alquilo inferior, halógeno, heteroarilo, CF3, OCF3, OCH2CF3, alcoxi inferior, CH2-alcoxi inferior, alquinilo inferior o ciano; X es un enlace, -NR’-, -CH2NH-, -CHR’’-, -(CH2)q-O- o -(CH2)2-; R’ es hidrógeno o alquilo inferior; R’’ es hidrógeno, alquilo inferior, alcoxi inferior; q es 0, 1 ó 2; o una sal de adición de ácido farmacéuticamente aceptable de los mismos. Reivindicación 3: Combinación según la reivindicación 2, que comprende olanzapina y un agonista de TAAR1 de fórmula (3) en la que R1 es hidrógeno, alquilo inferior, hidroxi, alcoxi inferior, alquilo inferior sustituido con halógeno, alcoxi inferior sustituido con halógeno o halógeno, en el que los sustituyentes para n = 2 pueden ser iguales o diferentes; X es un enlace, -NRCHR’, -CHRCHR’ o -OCHRCHR’; R/R’ puede ser, independientemente uno de otro, hidrógeno, alquilo inferior; n es 1 ó 2; o un agonista de TAAR1 de fórmula (2) en la que R es hidrógeno; R1 es pirrolidinilo; R2 es arilo o heteroarilo, en el que los anillos aromáticos se sustituyen opcionalmente con halógeno; X es un enlace o -NR’-; R’ es hidrógeno o alquilo inferior; o una sal de adición de ácido farmacéuticamente aceptable de los mismos. Reivindicación 4: Combinación según las reivindicaciones 1 a 3, que comprende olanzapina y un agonista de TAAR1, siendo los agonistas de TAAR1: S1 = (S)-4-((S)-2-fenil-butil)-4,5-dihidro-oxazol-2-ilamina, S2 = (S)-4-(3-fluoro-2-metil-fenil)-4,5-dihidro-oxazol-2-ilamina, S3 = (S)-4-(4-cloro-2-trifluorometil-fenil)-4,5-dihidro-oxazol-2-ilamina, S4 = (S)-4-[(etil-fenil-amino)-metil]-4,5-dihidro-oxazol-2-ilamina, S5 = 3-[(S)-1-((S)-2-amino-4,5-dihidro-oxazol-4-ilmetil)-propoxi]-fenol, S6 = (4-pirrolidin-3-il-fenil)-amida de ácido 5-cloro-piridin-2-carboxílico, S7 = 4-cloro-N-(4-pirrolidin-3-il-fenil)-benzamida, S8 = 1-(5-cloro-piridin-2-il)-3-(4-pirrolidin-3-il-fenil)urea, S9 = (S)-4-[(S)-1-(4-fluoro-fenil)-etoximetil]-4,5-dihidro-oxazol-2-ilamina, S10 = {4-[2-((S)-2-amino-4,5-dihidro-oxazol-4-il)-etil]-fenil}-amida de ácido 5-cloro-pirimidin-2-carboxílico, S11 = N-{4-[2-((S)-2-amino-4,5-dihidro-oxazol-4-il)-etil]-fenil}-4-cloro-benzamida, S12 = (R)-2-cloro-6-metil-N-(4-(morfolin-2-il)fenil)isonicotinamida, S13 = (S)-N-(4-(morfolin-2-il)fenil)-6-(2,2,2-trifluoroetoxi)nicotinamida, S14 = (S)-N-(4-(morfolin-2-il)fenil)-2-(trifluorometil)isonicotinamida, S15 = (S)-1-(4-fluorobencil)-3-(4-(morfolin-2-il)fenil)urea, S16 = (S)-1-(3-cianofenil)-3-(4-(morfolin-2-il)fenil)urea, y S17 = (S)-6-cloro-N-(4-(morfolin-2-il)fenil)nicotinamida. Reivindicación 5: Compuesto S2 = (S)-4-(3-fluoro-2-metil-fenil)-4,5-dihidro-oxazol-2-ilamina, comprendido por las fórmulas (1) ó (3) según las reivindicaciones 2 y 3. Reivindicación 6: Combinación según las reivindicaciones 1 a 4, que comprende olanzapina y un agonista de TAAR1 para el tratamiento de la esquizofrenia y de los episodios de manía asociados al trastorno bipolar, con una incidencia reducida de síndrome metabólico. Reivindicación 7: Combinación según la reivindicación 6, que comprende olanzapina y un agonista de TAAR1 para el tratamiento de la esquizofrenia y de los episodios de manía asociados al trastorno bipolar, con eficacia antidiabética. Reivindicación 9: Combinación según la reivindicación 8, que comprende olanzapina y un agonista de TAAR1 para el tratamiento de la esquizofrenia y de los episodios de manía asociados al trastorno bipolar, con eficacia antidiabética, que resulta en la reducción de la masa grasa y el peso corporal. Reivindicación 16: Método para el tratamiento de la esquizofrenia y los episodios maníacos asociados al trastorno bipolar según la reivindicación 15, en el que la incidencia reducida de síndrome metabólico resulta de la eficacia antidiabética con reducción de las excursiones de la glucosa sanguínea, la masa grasa y el peso corporal, que comprende administrar en un ser humano que necesita del mismo una cantidad efectiva de una combinación que comprende un fármaco antipsicótico atípico y un agonista de TAAR1.
ARP110102780 2010-08-02 2011-08-02 Combinacion que comprende un farmaco antipsicotico y un agonista de taar1 AR082458A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10171560 2010-08-02

Publications (1)

Publication Number Publication Date
AR082458A1 true AR082458A1 (es) 2012-12-12

Family

ID=44512842

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110102780 AR082458A1 (es) 2010-08-02 2011-08-02 Combinacion que comprende un farmaco antipsicotico y un agonista de taar1

Country Status (25)

Country Link
US (2) US9132136B2 (es)
EP (1) EP2600853A1 (es)
JP (2) JP5749802B2 (es)
KR (1) KR101455548B1 (es)
CN (1) CN103068379A (es)
AR (1) AR082458A1 (es)
AU (1) AU2011287701A1 (es)
BR (1) BR112013002518A2 (es)
CA (1) CA2802935A1 (es)
CL (1) CL2013000313A1 (es)
CO (1) CO6761298A2 (es)
CR (1) CR20120663A (es)
EA (1) EA024703B1 (es)
EC (1) ECSP13012414A (es)
MA (1) MA34458B1 (es)
MX (1) MX340489B (es)
MY (1) MY166955A (es)
NZ (1) NZ604592A (es)
PE (1) PE20130497A1 (es)
PH (1) PH12013500043A1 (es)
SG (1) SG187125A1 (es)
TW (1) TWI511728B (es)
UA (1) UA112527C2 (es)
WO (1) WO2012016879A1 (es)
ZA (1) ZA201300431B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8802673B2 (en) * 2011-03-24 2014-08-12 Hoffmann-La Roche Inc Heterocyclic amine derivatives
US9073911B2 (en) * 2011-06-09 2015-07-07 Hoffmann-La Roche Inc. Pyrazole derivatives
US9029370B2 (en) * 2011-06-10 2015-05-12 Hoffmann-La Roche Inc. Substituted benzamide derivatives
MX354815B (es) * 2012-01-12 2018-03-22 Hoffmann La Roche Derivados heterociclicos como receptores asociados con las aminas traza (taars).
EP2920150B1 (en) * 2012-11-16 2017-07-19 F. Hoffmann-La Roche AG Process for the preparation of 2-trifluoromethyl isonicotinic acid and esters
CN105793430B (zh) 2013-12-11 2020-03-03 豪夫迈·罗氏有限公司 用于制备手性2-芳基吗啉的方法
WO2015165085A1 (en) * 2014-04-30 2015-11-05 F.Hoffmann-La Roche Ag Morpholin-pyridine derivatives
EP3452473A1 (en) * 2016-05-04 2019-03-13 Purdue Pharma L.P. Oxazoline pseudodimers, pharmaceutical compositions and the use thereof
EA202091945A1 (ru) 2018-02-16 2021-01-18 Суновион Фармасьютикалз Инк. Соли, кристаллические формы и способы их получения
KR20210003160A (ko) 2018-04-18 2021-01-11 콘스텔레이션 파마슈티칼스, 인크. 메틸 변형 효소 조절제, 이의 조성물 및 용도
EP3797108B1 (en) 2018-05-21 2022-07-20 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
JP2023523569A (ja) 2020-04-14 2023-06-06 サノビオン ファーマシューティカルズ インク 神経学的および精神障害の治療方法
CA3178004A1 (en) * 2020-05-09 2021-11-18 Taolei Sun Treatment of adverse effects caused by atypical antipsychotics
CN116987095A (zh) * 2021-03-29 2023-11-03 上海枢境生物科技有限公司 含螺环类衍生物、其制备方法和应用
CN114288304A (zh) * 2021-12-31 2022-04-08 江苏海洋大学 一种抗精神分裂症组合物及其应用
AR129909A1 (es) 2022-07-15 2024-10-09 Hoffmann La Roche Cetorreductasa mutante con mayor actividad de cetorreductasa así como métodos y usos de esta

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7932249B2 (en) 2005-01-05 2011-04-26 Eli Lilly And Company Olanzapine pamoate dihydrate
WO2006115770A2 (en) * 2005-04-22 2006-11-02 Teva Pharmaceuticals Usa, Inc. Orally disintegrating pharmaceutical tablet formulations of olanzapine
KR20070022539A (ko) 2005-08-22 2007-02-27 홍진표 지프라시돈 또는 그의 대사산물을 함유하는 항비만 조성물
WO2008092785A1 (en) 2007-02-02 2008-08-07 F. Hoffmann-La Roche Ag Novel 2-aminooxazolines as taar1 ligands for cns disorders
RU2460725C2 (ru) 2007-02-15 2012-09-10 Ф. Хоффманн-Ля Рош Аг Новые 2-аминооксазолины в качестве лигандов taar1
CA2695071A1 (en) 2007-08-02 2009-02-05 F. Hoffmann-La Roche Ag The use of benzamide derivatives for the treatment of cns disorders
CA2728480A1 (en) 2008-07-24 2010-01-28 F. Hoffmann-La Roche Ag 4,5-dihydro-oxazol-2-yl derivatives
CN102143752B (zh) 2008-08-05 2014-12-10 奥默罗斯公司 Pde10抑制剂以及相关组合物和方法
US8354441B2 (en) 2009-11-11 2013-01-15 Hoffmann-La Roche Inc. Oxazoline derivatives
US9452980B2 (en) * 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
US8293954B2 (en) * 2010-03-10 2012-10-23 Honeywell International Inc. Catalyst life improvement for the vapor phase manufacture of 1-chloro-3,3,3-trifluoropropene

Also Published As

Publication number Publication date
EP2600853A1 (en) 2013-06-12
BR112013002518A2 (pt) 2016-05-31
AU2011287701A1 (en) 2013-01-10
EA024703B1 (ru) 2016-10-31
CL2013000313A1 (es) 2013-05-03
JP5749802B2 (ja) 2015-07-15
NZ604592A (en) 2015-02-27
WO2012016879A1 (en) 2012-02-09
MY166955A (en) 2018-07-25
JP2015145408A (ja) 2015-08-13
US9132136B2 (en) 2015-09-15
CN103068379A (zh) 2013-04-24
MX2013000745A (es) 2013-03-05
CR20120663A (es) 2013-04-01
CO6761298A2 (es) 2013-09-30
KR20130070629A (ko) 2013-06-27
JP2013536181A (ja) 2013-09-19
TWI511728B (zh) 2015-12-11
PE20130497A1 (es) 2013-04-22
ECSP13012414A (es) 2013-03-28
PH12013500043A1 (en) 2019-06-03
MA34458B1 (fr) 2013-08-01
UA112527C2 (uk) 2016-09-26
ZA201300431B (en) 2013-09-25
SG187125A1 (en) 2013-02-28
US20130345201A1 (en) 2013-12-26
MX340489B (es) 2016-07-11
US20120028964A1 (en) 2012-02-02
KR101455548B1 (ko) 2014-10-27
CA2802935A1 (en) 2012-02-09
TW201206912A (en) 2012-02-16
EA201291476A1 (ru) 2013-06-28

Similar Documents

Publication Publication Date Title
AR082458A1 (es) Combinacion que comprende un farmaco antipsicotico y un agonista de taar1
JP2016538313A5 (es)
RU2012127760A (ru) Bcl-2-селективные апоптоз-индуцирующие средства для лечения рака и иммунных заболеваний
NZ612544A (en) Heterocyclic compounds suitable for the treatment of dyslipidemia
RU2010137114A (ru) Амидные производные как позитивные аллостерические модуляторы и способы их применения
NZ588652A (en) Carboxamide compounds for the treatment of metabolic disorders
RU2017120217A (ru) 2-амино-5,5-дифтор-6-(фторметил)-6-фенил-3,4,5,6-тетрагидпропиридины в качестве ингибиторов bace1
RU2017116598A (ru) Соединения и композиции для модуляции киназной активности мутантов egfr
RU2010110640A (ru) Соединения и композиции 5-(4-(галогеналкокси)фенил)пиримидин-2-амина в качестве ингибиторов киназ
RU2012116877A (ru) Соединения 2-пиридона, применяемые в качестве ингибиторов нейтрофильной эластазы
PE20120650A1 (es) Acetamidas sustituidas por n-(hetero)-arilo y 2-(hetero)-arilo, como moduladores de la senalizacion de wnt
ME02315B (me) Novi antimalarijski agensi
RU2006145205A (ru) Терапевтические соединения: пиридин в качестве каркаса
HRP20100522T1 (hr) Piridin karboksamidi kao inhibitori 11-beta-hsd1
RU2012127790A (ru) Индуцирующие апоптоз агенты для лечения рака и иммунных и аутоиммунных заболеваний
HRP20160287T1 (hr) Antagonisti cgrp receptora
HRP20201430T1 (hr) Spojevi 6-heterociklil-4-morfolin-4-ilpiridin-2-ona korisni za liječenje karcinoma i dijabetesa
RU2008135690A (ru) Соединения и композиции в качестве ингибиторов протеинкиназы
NZ597528A (en) Inhibitors of flaviviridae viruses
RU2004126936A (ru) Производные хинолина в качестве антагонистов npv
JP2013516395A5 (es)
RU2017121044A (ru) Производные амидотиадиазола в качестве ингибиторов надфн-оксидазы
RU2015116816A (ru) Производное имидазола
RU2018104868A (ru) 2-амино-3-фтор-3-(фторметил)-6-метил-6-фенил-3,4,5,6-тетрагидропиридины в качестве ингибиторов bace1
PE20130215A1 (es) Nuevos derivados de ciclohexilamina que tienen actividad como agonistas adrenergicos beta2 y como antagonistas muscarinicos m3

Legal Events

Date Code Title Description
FB Suspension of granting procedure